Migraine – Emerging Therapies – Aimovig-Migraine Prevention – Migraine Prophylaxis Wave 1 (US)
Market Outlook
The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional anti-CGRP monoclonal antibodies (MAbs) racing to market. Aimovig is in the pole position as the first migraine-specific preventive therapy, the first major new entrant, and the first MAb to enter this highly underserved but heavily generic market since the approval of Allergan’s Botox in 2010. This U.S.-based launch-tracking series—DRG’s first in migraine—assesses Aimovig’s uptake and performance through year 1. Similar series to track the launches of future MAb competitors are also planned.
QUESTIONS ANSWERED
- How quickly are U.S. neurologists adopting Aimovig, and what percentage of their migraine patients do they consider candidates for the drug?
- When and for which migraine patients are neurologists prescribing Aimovig, what are the reasons for prescribing, and how satisfied are they with the drug?
- How do adopters and nonadopters of Aimovig compare across key metrics? What attributes differentiate Aimovig from competing MAbs in the minds of prescribers?
- What promotional messages do neurologists recall in support of the Aimovig launch?
PRODUCT DESCRIPTION
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch in a survey of U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product as well as the impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Markets covered: United States.
Primary research: Survey of 75 U.S. neurologists for each wave.
Key metrics included:
- Unaided and aided awareness of Aimovig.
- Familiarity with and impressions of Aimovig.
- Prescriber and nonprescriber profiles.
- Willingness to prescribe Aimovig.
- Performance of Aimovig on key attributes.
- Sales representative visit frequency, reach, and satisfaction among physicians.
- Benchmarking against other anti-CGRPMAbs (if/when they are launched).
Table of contents
- Migraine - Emerging Therapies - Aimovig-Migraine Prevention - Migraine Prophylaxis Wave 1 (US)
- Migraine - Emerging Therapies: Aimovig Wave 1 - August 2018
Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain.
Dr. Sparrow holds a Ph.D. in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.